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CD1d-dependent immune suppression mediated by
regulatory B cells through modulations of
iNKT cells
K. Oleinika1,2, E.C. Rosser1,3, D.E. Matei1, K. Nistala1, A. Bosma1, I. Drozdov4 & C. Mauri 1
Regulatory B cells (Breg) express high levels of CD1d that presents lipid antigens to invariant
natural killer T (iNKT) cells. The function of CD1d in Breg biology and iNKT cell activity during
inﬂammation remains unclear. Here we show, using chimeric mice, cell depletion and
adoptive cell transfer, that CD1d–lipid presentation by Bregs induces iNKT cells to secrete
interferon (IFN)-γ to contribute, partially, to the downregulation of T helper (Th)1 and Th17-
adaptive immune responses and ameliorate experimental arthritis. Mice lacking CD1d-
expressing B cells develop exacerbated disease compared to wild-type mice, and fail to
respond to treatment with the prototypical iNKT cell agonist α-galactosylceramide. The
absence of lipid presentation by B cells alters iNKT cell activation with disruption of meta-
bolism regulation and cytokine responses. Thus, we identify a mechanism by which Bregs
restrain excessive inﬂammation via lipid presentation.
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Regulatory B cells (Breg) are effectors of immune tolerance
1.
Although the hallmark of Breg function is the production
of interleukin (IL)-102, additional Breg-mediated suppres-
sion mechanisms include transforming growth factor-β (TGF-β)3,
IL-354 release, and PD-L1 expression5. Bregs express different
surface markers, including CD21, CD23, CD24, CD5, T cell
immunoglobulin and mucin domain (TIM)-1, and CD1386. A
marker that is expressed by the majority of reported Breg subsets,
in both mice and humans, is CD1d1,7. Yet, the functional rele-
vance of CD1d for Breg-suppressive function remains to be
elucidated.
CD1d is a major-histocompatibility-complex (MHC) class-I-
like molecule, which presents self-lipid and non-self-lipid anti-
gens to invariant natural killer T (iNKT) cells8. Following
engagement of the invariant T cell receptor (iTCR) by
CD1d–lipid complexes, iNKT cells proliferate, produce cytokines,
and become cytotoxic, regulating innate and adaptive immune
responses9. iNKT cells are involved in the enhancement of anti-
tumor immunity, protection against infections, and regulation of
autoimmunity10. In the latter context, administration of α-
galactosylceramide (α-GalCer), the prototypical iNKT cell gly-
colipid agonist, has been shown to suppress the development of
autoimmunity in mice11–13. In humans, numerical and functional
defects in iNKT cells have been reported in systemic lupus ery-
thematosus (SLE)1,14,15, rheumatoid arthritis (RA)14–16, and
multiple sclerosis17. If and how decreased iNKT cell number or
function contributes to autoimmunity remains unknown.
While α-GalCer presentation by B cells to iNKT cells results in
the differentiation of antibody-producing B cells by a feedback
mechanism18,19, whether Bregs by interacting with iNKT cells
condition their responses remains less explored. We have shown
that B cells from SLE patients with active disease express
decreased levels of CD1d and do not support the expansion and
activation of iNKT cells upon in vitro stimulation with α-GalCer1.
In SLE patients responding to B cell-depletion therapy, where a
repopulation in naive and transitional B cells with regulatory
function is reported20,21, the CD1d recycling defect on B cells was
reversed. iNKT cell frequency and function are normalized in the
peripheral blood of these patients, suggesting a B-iNKT cell
interaction1. These results raise two questions: can Bregs instruct
iNKT cells with suppressive function, and does the impaired
CD1d+ Breg lipid presentation to iNKT cells exacerbate auto-
immune responses?
Here, we report a role for CD1d+T2-MZP Bregs in the dif-
ferentiation of suppressive iNKT cells that restrain excessive
arthritogenic T helper (Th)1/Th17 responses, partially via the
production of interferon (IFN)-γ. The induction of promyelocytic
leukemia zinc ﬁnger (PLZF)+IFN-γ+ iNKT cells in response to α-
GalCer treatment occurs only in CD1d B cell-competent mice
and is independent of B cell production of IL-10. CD1d–lipid
presentation by B cells is required to ﬁne-tune the expression of
genes involved in cytokine responses, metabolism, and other
pathways related to immune cell activation and effector function
in iNKT cells. We also demonstrate that, upon MZ B cell
depletion, T2-MZP B cells continue to induce the differentiation
of immunosuppressive iNKT cells. Our study suggests that lipid
presentation by Bregs, and consequent induction of suppressive
iNKT cells, could be a way to increase immune tolerance for the
control of autoimmune diseases.
Results
B cells mediate α-GalCer amelioration of arthritis. To address
the role that B cells play in α-GalCer-iNKT cell-driven ameli-
oration of arthritis, B cell-deﬁcient (μMT) and WT mice were
immunized to induce arthritis and treated with α-GalCer (to
promote interactions with CD1d-expressing cells). α-GalCer
treatment suppressed the development of arthritis in WT mice,
while it failed to inhibit the disease in μMT mice (Fig. 1a).
Clinical scores were recorded up to either day 3 or day 7
according to the experimental design. An example of disease
development in WT mice is shown in Supplementary Fig. 1a. In
response to α-GalCer, we observed an equal increase in the fre-
quencies and absolute numbers of iNKT cells in the spleen
(Fig. 1b), inguinal lymph nodes, and the liver of μMT and WT
mice (Supplementary Fig. 1b–c). Splenic iNKT cells from both α-
GalCer-treated μMT and WT mice expressed comparable levels
of Ki-67, suggesting that α-GalCer-driven proliferation of
iNKT cells was normal in the absence of B cells (Fig. 1c).
PLZF is responsible for the innate-like effector phenotype of
iNKT cells and rapid cytokine production, including IFN-γ22,23,
which has also been associated with iNKT cell suppressive
function24–27. We observed that in the absence of B cells, iNKT
cell ability to upregulate the expression of PLZF and IFN-γ in
response to α-GalCer was signiﬁcantly impaired compared to WT
mice in the spleen (p< 0.01 and p< 0.001 by one-way analysis of
variance (ANOVA)) (Fig. 1d, e). This is in contrast to the liver
where α-GalCer-induced iNKT cells expressed comparable levels
of PLZF and IFN-γ in μMT and WT mice (Fig. 1f, g). We also
report a reduction of IL-4-expressing iNKT cells in response to α-
GalCer in μMT mice compared to WT mice. The frequency of IL-
4+ iNKT cells was overall lower than that of the IFN-γ+
iNKT cells. IL-10, IL-13, and GM-CSF were not differentially
expressed under the same experimental conditions (Supplemen-
tary Fig. 1d). We could not detect FoxP3+28 or E4BP4+
iNKT cells29, previously ascribed with regulatory function in
the lymph nodes and adipose tissue, respectively, in the spleens of
α-GalCer-treated mice (Supplementary Fig. 1e, f).
μMT mice lack B cells from birth, which could impair the
development of iNKT cells. To explore the role of B cells in lipid
presentation in an environment where iNKT cells have developed
in the presence of B cells, adult WT mice were treated either with
a depleting anti-CD20 or isotype-control antibody. Mice were
then immunized and treated with α-GalCer. The administration
of anti-CD20 antibody depleted over 98.9% of B cells in the
spleens of mice (Fig. 2a). In agreement with the results observed
in μMT mice, α-GalCer treatment ameliorated the disease in
control but not in B cell-depleted mice (Fig. 2b). The frequencies
and numbers of iNKT cells were similar between B cell-depleted
and control mice, with or without α-GalCer treatment (Fig. 2c). A
signiﬁcant increase in the expression of PLZF and IFN-γ in
iNKT cells, following treatment with α-GalCer, was observed in
control mice (p< 0.01 and p< 0.0001 by one-way ANOVA), but
their upregulation was signiﬁcantly lower in B cell-depleted mice
(p< 0.01 and p< 0.0001 by one-way ANOVA) (Fig. 2d, e).
As CD11c+ dendritic cells (DC) play an important role in lipid
presentation and iNKT cell priming, next, we selectively depleted
DCs and assessed their effect on iNKT cells in AIA. Diphtheria
toxin was administered to mice that express the diphtheria toxin
receptor (DTR) under the control of the Cd11c promoter31. Due
to the important role that DCs play in the early phase of arthritis
induction, α-GalCer was, in this instance, administered 8 h after
intra-articular injection of mBSA and intraperitoneal adminis-
tration of diphtheria toxin. α-GalCer-mediated suppression of
arthritis in CD11c+ cell-depleted mice was equivalent to control
mice (Supplementary Fig. 2a–c). The upregulation of PLZF and
the early “burst” of IFN-γ by iNKT cells in response to α-GalCer
was not affected by the lack of DCs (Supplementary Fig. 3a, b).
While there was a numerical reduction of iNKT cells in CD11c+
cell-depleted mice compared to controls at 72 h, this was
observed following the peak IFN-γ production at 16 h, when the
iNKT cell numbers were comparable (Supplementary Fig. 3c, d).
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Fig. 1 α-GalCer-iNKT-cell-dependent amelioration of arthritis requires B cells. a Mean clinical score of wild-type (WT) mice (left) and μMT mice (right)
that received α-GalCer or vehicle alone following induction of arthritis. The Y axis shows the percentage of swelling in antigen-injected knee compared to
control knee (μMT± α-GalCer n= 14 per group, WT± α-GalCer n= 20 per group, one of three experiments is shown). b Representative ﬂow cytometry
plots and bar charts showing the frequency and number of splenic iNKT cells in μMT and WT mice that received α-GalCer or vehicle alone (n= 5 per
group, one of three experiments is shown). c Representative histograms and bar chart showing median ﬂuorescence intensity (MFI) of Ki-67 in splenic
iNKT cells from α-GalCer- or vehicle-treated μMT and WT mice (n= 3 per group, one of three experiments is shown). d Representative histograms and bar
chart showing MFI of PLZF in splenic iNKT cells from α-GalCer- or vehicle-treated μMT andWT mice (n= 3 per group, one of three experiments is shown).
e Representative ﬂow cytometry plots and bar chart showing the frequency of IFN-γ+ splenic iNKT cells from α-GalCer- or vehicle-treated μMT and WT
mice (n= 4 per group, one of three experiments is shown). f Representative histograms and bar chart showing MFI of PLZF in hepatic iNKT cells from α-
GalCer- or vehicle-treated μMT and WT mice (n= 3 per group, one of two experiments is shown). g Representative ﬂow cytometry plots and bar chart
showing the frequency of IFN-γ+ hepatic iNKT cells from α-GalCer- or vehicle-treated μMT and WT mice (n= 4 per group, one of three experiments is
shown). b, c Analyzed on day 3 post disease onset, d–g analyzed at 16 h post disease onset. Data are mean± s.e.m. ns not signiﬁcant, *p< 0.05, **p< 0.01,
***p< 0.001, and ****p< 0.0001 (a two-way analysis of variance (ANOVA), b–g one-way ANOVA)
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Of interest, the induction of iNKT cell IFN-γ production precedes
their expansion (Supplementary Fig. 3e, f).
Next, we depleted B cells or DCs from splenocytes of arthritic
mice before stimulating them in vitro with α-GalCer and IL-2.
Only B cell depletion led to reduced iNKT cell PLZF and IFN-γ
expression, compared to control and DC-depleted splenocytes.
DC depletion led to decreased expression of CD25 and CD69 by
iNKT cells (Supplementary Fig. 3g). These data show that while B
cells are responsible for driving the expression of iNKT cell PLZF
e
Vehicle α-GalCer
IF
N
-γ
CD1d-tetramer
C
on
tr
ol
B
 c
el
l d
ep
le
te
d
15.6 48.3
13.6 26.6 Control B cell
depleted
– + – +α-GalCer
a b
60
Control - α-GalCer
Control - vehicle
0 1 2 3
0
20
40
Day post disease onset
In
cr
ea
se
 in
 k
ne
e 
sw
el
lin
g
co
m
pa
re
d 
to
 c
on
tr
ol
 k
ne
e 
(%
)
*
0 1 2 3
0
20
40
60
Day post disease onset
In
cr
ea
se
 in
 k
ne
e 
sw
el
lin
g
co
m
pa
re
d 
to
 c
on
tr
ol
 k
ne
e 
(%
)
B cell depleted - α-GalCer
B cell depleted - vehicle
Day –21 Day –7 Day 0
i.a. mBSA-PBS or PBS
i.p. α-GalCer or vehicle
s.c. mBSA-CFA
Day –14
i.p. anti-CD20 or
isotype control mAbs
d
Iso
 co
nt
ro
l
An
ti-
CD
20
0
10
20
30
40
C
D
19
+
 B
 c
el
ls
 (
%
) ***
0
10
20
30
C
D
19
+
 B
 c
el
ls
 (
x1
06
) ****
Iso
 co
nt
ro
l
An
ti-
CD
20
0
1
2
3
4
iN
K
T
 c
el
ls
 (
×
10
6 ) * *
0
1
2
3
4
5
iN
K
T
 c
el
ls
 (
%
)
** **
C
on
tr
ol
B
 c
el
l d
ep
le
te
d
C
D
1d
-t
et
ra
m
er
CD3
1.22 3.15
1.25 3.55
Vehicle α-GalCer
Gated on live CD19– cellsc
Control B cell
depleted
– + – +α-GalCer
Control B cell
depleted
– + – +α-GalCer PLZF
Gated on live CD19–
CD1d-tetramer+CD3int cells
Control - vehicle
Control - α-GalCer
B cell depleted - α-GalCer
B cell depleted - vehicle
Control B cell
depleted 
– + – +α-GalCer
00 1030
0
103
103
104
104
105
105
–103
–103
0
103
104
105
–103
0
103
104
105
–103
0
103
104
105
–103
0 103 104 105–103
0
0
103
103
104
105
106
0
103
104
105
106
0
103
104
105
106
0
103
104
105
106
0
103
104
105
106
104 105–103
0 103 104 105–103
0 103 104 105–103
0 103 104 105–103 0 103 104 105–103
0 103 104 105–103
0 103 104 105–103
100
200
300
400
500
P
LZ
F
 (
M
F
I)
** **
0
10
20
30
40
50
IF
N
-γ
+
 iN
K
T
 c
el
ls
 (
%
)
***
****
****
ns ns
ns
0
IF
N
-γ
CD3
FMO
Gated on live CD19–CD1d-tetramer+CD3int cells
Fig. 2 B cell depletion abrogates the protective effect of α-GalCer on arthritis. a Left, schematic showing the experimental design for B cell depletion. Right,
bar charts showing the frequency and number of splenic CD19+ B cells in B cell-depleted and isotype-control-treated WT mice prior to α-GalCer or vehicle
administration (n= 5 per group, one of three experiments is shown). b Mean clinical score of isotype-control-treated WT mice (left) and B cell-depleted
WT mice (right) that received α-GalCer or vehicle alone following induction of arthritis. The Y axis shows the percentage of swelling in antigen-injected
knee compared to control knee (n= 5 per group, one of two experiments is shown). c Representative ﬂow cytometry plots and bar charts showing the
frequency and number of splenic iNKT cells in B cell-depleted and isotype-control-treated WT mice that received α-GalCer or vehicle alone (n= 5 per
group, one of two experiments is shown). d Representative histograms and bar chart showing MFI of PLZF in splenic iNKT cells in B cell-depleted and
isotype-control-treated WT mice that received α-GalCer or vehicle alone (n= 3 per group, one of two experiments is shown). e Representative ﬂow
cytometry plots and bar chart showing the frequency of IFN-γ+ splenic iNKT cells in B cell-depleted and isotype-control-treated WT mice that received α-
GalCer or vehicle alone (n= 4 per group, one of two experiments is shown). c Analyzed on day 3 post disease onset; d, e analyzed at 16 h post disease
onset. Data are mean± s.e.m. ns not signiﬁcant, *p< 0.05, **p< 0.01, ***p< 0.001, and ****p< 0.0001 (a Student’s t test, b two-way ANOVA, and c–e
one-way ANOVA)
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and IFN-γ, CD11c+ DCs are required for iNKT cell expansion
and activation.
CD1d+ B cells induce IFN-γ+PLZF+ iNKT cells. To ascertain
whether B cells interact with iNKT cells directly via CD1d, we
generated chimeric mice lacking CD1d on B cells (B-Cd1d−/−)
and control chimeras (B-WT) (Supplementary Fig. 4a).
B-Cd1d−/− mice developed exacerbated disease compared to B-
WT mice, suggesting a role for endogenous lipid presentation by
B cells in controlling the severity of arthritis (Supplementary
Fig. 4b). To assess the importance of B cells expressing CD1d in
the differentiation of iNKT cells that limit the disease, we treated
B-Cd1d−/− and B-WT mice with α-GalCer. While α-GalCer
suppressed disease development in B-WT mice compared to
vehicle-treated B-WT mice, B-Cd1d−/− mice failed to respond to
the treatment (Fig. 3a). α-GalCer-induced inhibition of the dis-
ease in B-WT mice was accompanied by a reduction in the fre-
quency and absolute number of IFN-γ+ and IL-17+CD4+ T cells
(Fig. 3b). The frequency of IFN-γ+ and IL-17+CD4+ T cells on
days 3 and 7 is comparable (Supplementary Fig. 4c).
iNKT cell expansion and proliferation in response to α-GalCer
were comparable in B-Cd1d−/− and B-WT mice (Fig. 3c, d). Upon
α-GalCer treatment, we observed a signiﬁcant decrease in PLZF
expression by iNKT cells and a decrease in the frequency of
IFN-γ+PLZF+ iNKT cells in B-Cd1d−/− compared to B-WT mice
(p< 0.01 and p< 0.05 by one-way ANOVA) (Fig. 3e, f). We
report a decrease in the MFI value of T-bet and an increase in
GATA3 expression in iNKT cells from B-Cd1d−/− compared to B-
WT mice in response to α-GalCer (Fig. 3g). These data show that
B cell CD1d is critical for the induction of iNKT cells that restrain
arthritogenic responses.
It has been previously suggested that iNKT cells regulate the
germinal center (GC) entry of B cells and that this is CD1d+ B
cell-dependent32. Amelioration of the disease by α-GalCer in B-
WT mice was accompanied by a decrease in the number of GCs
compared to vehicle-treated mice (Supplementary Fig. 4d). This
reduction was controlled by CD1d+ B cells, since α-GalCer-driven
decrease in GCs was not observed in B-Cd1d−/− mice. In WT
mice, α-GalCer treatment caused a reduction in Tfh cells
compared to the vehicle-treated group, whereas iNKTfh cells
were not signiﬁcantly changed between the two groups (p> 0.05
by Student’s t test) (Supplementary Fig. 4e). Following α-GalCer
treatment, iNKT cells were found in close proximity to IgDhiB
cells in the T cell area of the spleen in B-WT mice, but not in B-
Cd1d−/− mice (Fig. 3h).
To assess whether in addition to CD1d, Bregs required IL-10 to
induce suppressive iNKT cells, we generated mice lacking IL-10-
producing B cells (B-Il10−/−) and WT (B-WT) chimeras
(Supplementary Fig. 4a). α-GalCer ameliorated the disease in B-
Il10−/− and B-WT mice (Fig. 3i). No difference between the
expression of CD1d on splenic B cells or on other cells between B-
Il10−/− and B-WT mice was observed (Supplementary Fig. 5a).
We found that α-GalCer treatment ameliorated arthritis in global
Il10ra−/− mice, just as in WT mice (Supplementary Fig. 5b).
These data suggest that IL-10 is not required for the differentia-
tion of suppressive iNKT cells.
CD1d+ B cells control iNKT cell transcriptional proﬁle. To
understand the mechanism underlying the suppressive capacity of
iNKT cells conferred by B cell lipid presentation, we proﬁled the
transcriptomes of iNKT cells sorted from α-GalCer- or vehicle-
treated B-Cd1d−/− and B-WT mice using RNA-seq. iNKT cell
purity was >95% (Supplementary Fig. 6). α-GalCer had similar
effects on the majority of gene expression in iNKT cells from B-
Cd1d−/− and B-WT mice (Fig. 4a). However, 3826 genes were
signiﬁcantly differentially expressed in α-GalCer-treated
B-Cd1d−/− and B-WT mice (p< 0.05 by QL F test). Among
these were those encoding immune-related genes essential for T
and iNKT cell effector function (Supplementary Fig. 7a). Of
interest, Zbtb16, which encodes PLZF, was expressed at sig-
niﬁcantly higher levels in iNKT cells from B-WT than from B-
Cd1d−/− mice following α-GalCer treatment (p< 0.05 by QL F
test), corroborating the results shown in Fig. 3e.
To understand the aspects of iNKT cell function regulated by B
cell lipid antigen presentation, we enriched differentially
expressed genes from α-GalCer-treated B-Cd1d−/− and B-WT
mice for overrepresented pathways. This analysis revealed gene
sets encoding products involved in the cell cycle, NK cell-
mediated cytotoxicity, as well as cytokine–cytokine receptor
interaction (Fig. 4b).
A substantial increase in the bioenergetic demands over the
resting state is a deﬁning feature of T cell activation33,34. Analysis
of metabolic pathways showed that in α-GalCer-treated
B-Cd1d−/− mice, iNKT cells were highly anabolic and presented
an increase in genes encoding enzymes involved in glycolysis and
a reduction in those involved in fatty acid oxidation compared to
B-WT mice with α-GalCer treatment (Fig. 4c). In particular,
crucial mediators of the metabolic switch in effector T cells,
namely Irf4, Myc, and Hif1a33,34, were signiﬁcantly increased in
B-Cd1d−/− compared to B-WT mice following α-GalCer treat-
ment (p< 0.05 by QL F test) (Supplementary Fig. 7a).
iNKT cells have been assigned, similarly to T helper cells, into
subsets according to their transcription factor and cytokine
proﬁle35,36. To further elucidate whether lipid presentation by B
cells skewed the response of iNKT cells toward a speciﬁc effector
subset, we compared the expression of cytokine genes by
iNKT cells from B-Cd1d−/− and B-WT mice with or without α-
GalCer treatment. The expression of most cytokines was
enhanced by the absence of CD1d-expressing B cells in α-
GalCer-treated mice, suggesting that B cells have a different role
in iNKT cell activation compared to other antigen-presenting
cells. For instance, we found an increase of Il21, Il9, Il10, and
Il17a in iNKT cells from B-Cd1d−/− compared to B-WT mice
following α-GalCer treatment (Fig. 4d). Increased frequencies of
IL-10+ and IL-13+ iNKT cells in the absence of CD1d-expressing
B cells in α-GalCer-treated mice were also detected by
intracellular staining, whereas no positive staining in iNKT cells
was found for IL-9, IL-17, and IL-21 (Supplementary Fig. 7b, c).
The transcriptional proﬁles of iNKT cells isolated from
B-Cd1d−/− and B-WT mice treated with α-GalCer or vehicle
control did not overlap with those previously assigned to sorted
thymic NKT1, NKT2, and NKT17 cells36 (Supplementary Fig. 7d).
However, at transcriptome-wide level, changes have to be
extensive to establish similarity. In addition, in our experiments,
iNKT cells were obtained from the spleens of mice during acute
inﬂammation, rather than from the thymus at steady state as
previously reported. Therefore, we compared the transcripts that
were identiﬁed as most signiﬁcantly enriched in NKT1, NKT2,
and NKT17 cells relative to the other subsets. Among signiﬁcant
genes that were differentially expressed (p< 0.05 by QL F test),
there was an overall skew away from NKT1 and toward NKT2
phenotype in B-Cd1d−/− mice compared to B-WT mice after α-
GalCer treatment (Fig. 4e). This change in transcriptional proﬁle
was consistent with the results reported in Fig. 3g showing a lack
of upregulation of T-bet, and an upregulation of GATA3
expression in B-Cd1d−/− mice compared to B-WT mice following
α-GalCer treatment. A low number of genes, previously
associated with NKT17 cells, were signiﬁcantly expressed in
iNKT cells from B-Cd1d−/− mice compared to B-WT mice
following α-GalCer treatment (p< 0.05 by QL F test) (Supple-
mentary Fig. 7e).
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We have consistently shown that upon α-GalCer treatment, the
expression of PLZF by iNKT cells from B cell-deﬁcient or
B-Cd1d−/− mice is reduced compared to the control group.
Therefore, we compared our α-GalCer-treated data sets to 99
genes previously identiﬁed as PLZF targets and found that 39 of
these transcripts were signiﬁcantly differentially expressed (p<
0.05 by QL F test), with 36 downregulated in the absence of B
cells expressing CD1d. This is consistent with an induction of an
iNKT cell PLZF signature supported by B cell CD1d. Of interest,
Bach2, a known repressor of effector differentiation in naive
T cells37, and previously shown to be bound to and repressed by
PLZF, was signiﬁcantly upregulated in iNKT cells of B-Cd1d−/−
mice compared to B-WT mice after α-GalCer administration (p
< 0.05 by QL F test) (Fig. 4f). Thus, iNKT cell suppression of
arthritis is dependent on B cell-driven calibration of iNKT cell
cytokine response, as well as pathways in iNKT cells associated
with effector function and metabolism.
iNKT cells inhibit Th1 and Th17 responses partially via IFN-γ.
Our results show the inhibition of Th1 and Th17 responses
associated with increased IFN-γ production by iNKT cells, and it
has been demonstrated that IFN-γ can be protective in auto-
immunity, including in AIA38. Thus, we investigated whether
IFN-γ produced by iNKT cells inhibits Th1 and Th17 responses
in our model. We neutralized IFN-γ in vivo24 prior to α-GalCer
or vehicle treatment, aiming to block α-GalCer-driven iNKT cell
IFN-γ. α-GalCer-treated control mice, which were protected from
the disease (Fig. 5a), displayed lower adaptive IFN-γ and IL-17
production compared to control mice that received vehicle
(Fig. 5b and Supplementary Fig. 8). In contrast, neutralization of
IFN-γ reduced the suppressive effect of α-GalCer on clinical
disease and prevented α-GalCer treatment from reducing the
frequency and number of Th1 and Th17 cells. This supports the
notion that α-GalCer-induced innate production of IFN-γ has a
role in the protection from arthritis and inhibition of adaptive
responses.
To understand whether B cell-driven IFN-γ by iNKT cells plays
a role in suppressing Th1 and Th17 cells, we used an in vitro
suppression assay in which splenocytes, isolated from arthritic
μMT or WT mice, were challenged with anti-CD3 (to stimulate
CD4+ T cells) and α-GalCer in the presence of anti-IFN-γ. We
observed signiﬁcant downregulation in the expression of T-bet
and ROR-γt (transcription factors for Th1 and Th17 cells,
respectively) in CD4+ T cells from WT mice (p< 0.05 by one-way
ANOVA), but not in CD4+ T cells from μMT mice after α-
GalCer stimulation (Fig. 5c). Neutralization of IFN-γ abolished
the α-GalCer-driven suppression of T-bet and ROR-γt in WT
CD4+ T cells. No signiﬁcant effect on GATA3 expression in CD4
+ T cells from WT or μMT mice by α-GalCer was observed (p>
0.05 by one-way ANOVA) (Fig. 5c).
To ascertain whether iNKT cells directly inhibit pathogenic
T cells, iNKT cells were isolated from arthritic α-GalCer-treated
μMT or WT mice, and then cultured with CD4+ T cells, isolated
from arthritic WT mice, in the presence of anti-IFN-γ or isotype-
control antibodies. WT and not μMT iNKT cells signiﬁcantly
inhibited WT CD4+ T cell expression of IFN-γ (p< 0.05 by one-
way ANOVA) (Fig. 5d). The inhibitory effect of WT iNKT cells
on CD4+ T cells was abolished upon IFN-γ neutralization
in vitro.
Given that blocking IFN-γ, in vivo and in vitro, ablated the
ability of α-GalCer-stimulated iNKT cells to suppress Th1 and
Th17 cells, we next assessed whether IFN-γ could directly inhibit
the responses of Th1 and Th17 cells in vitro. We stimulated CD4+
T cells, isolated from spleens of mice with arthritis, with anti-CD3
and increasing doses of IFN-γ. The frequency of both T-bet+ and
ROR-γt+CD4+ T cells was signiﬁcantly reduced as the concentra-
tions of IFN-γ were increased (p< 0.001 and p< 0.0001 by one-
way ANOVA) (Fig. 5e). These results support the notion that
Breg-induced innate production of IFN-γ by iNKT cells has a role
in the suppression of inﬂammation and inhibition of adaptive
Th1/Th17 responses.
T2-MZP Bregs via CD1d induce suppressive iNKT cells. Based
on our ﬁndings showing that B cells are important in mediating
suppression conferred by α-GalCer, we hypothesized that T2-
MZP B cells, known to express high levels of CD1d (Supple-
mentary Fig. 9a–c) and to suppress different autoimmune dis-
eases39, induced the differentiation of iNKT cells that ameliorate
the disease. We adoptively transferred T2-MZP B cells (the purity
of sorted subsets is shown in Supplementary Fig. 10), isolated
from the spleens of WT mice in remission from arthritis, into WT
and Cd1d−/− mice that lack iNKT and type II NKT cells40,41. As
previously shown, T2-MZP Bregs suppressed arthritis and
reduced the frequency and absolute number of IFN-γ+ and IL-17
+CD4+ T cells in WT mice; however, WT T2-MZP Bregs were
unable to convey the same suppressive effect in iNKT cell-
Fig. 3 B cell-speciﬁc CD1d is critical for α-GalCer-iNKT cell amelioration of arthritis. a Mean clinical score of B-WT chimeric mice (left) and B-Cd1d−/−
chimeric mice (right) that received α-GalCer or vehicle alone following induction of arthritis. The Y axis shows the percentage of swelling in antigen-
injected knee compared to control knee (B-Cd1d−/−± α-GalCer n= 5 per group, B-WT± α-GalCer n= 4 per group, one of three experiments is shown). b
Representative ﬂow cytometry plots and bar charts showing the frequency (top) and number (bottom) of splenic IFN-γ+ and IL-17+ CD4+ T cells in
B-Cd1d−/− and B-WT chimeric mice that received α-GalCer or vehicle alone (n= 3 per group, one of two experiments is shown). c Representative ﬂow
cytometry plots and bar charts showing the frequency and number of splenic iNKT cells in B-Cd1d−/− and B-WT mice that received α-GalCer or vehicle
alone (n= 3 per group, one of two experiments is shown). d Representative histograms and bar chart showing MFI of Ki-67 in splenic iNKT cells from α-
GalCer- or vehicle-treated B-Cd1d−/− and B-WT mice (n= 3 per group, one of two experiments is shown). e Representative histograms and bar chart
showing MFI of PLZF in splenic iNKT cells from α-GalCer- or vehicle-treated B-Cd1d−/− and B-WT mice (n= 3 per group, one of two experiments is shown).
f Representative ﬂow cytometry plots and bar chart showing the frequency of IFN-γ+PLZF+ splenic iNKT cells from α-GalCer- or vehicle-treated B-Cd1d−/−
and B-WT mice (n= 4 per group, one of two experiments is shown). g Representative histograms and bar charts showing MFI of T-bet and GATA3 in
splenic iNKT cells from α-GalCer- or vehicle-treated B-Cd1d−/− and B-WT mice (n= 3 per group, one of two experiments is shown). h Representative
immunoﬂuorescence showing the localization of splenic NK1.1+CD3+ T cells and IgD+ B cells in B-Cd1d−/− and B-WT chimeric mice that received α-GalCer
or vehicle alone. Arrowheads point to NK1.1+CD3+ cells. Bar, 100 μm, inset bar, 5 μm (n= 3 per group, one of two experiments is shown). i Mean clinical
score of B-Il10−/− chimeric mice (right) and B-WT chimeric mice (left) that received α-GalCer or vehicle alone following induction of arthritis; the Y axis
shows the percentage of swelling in antigen-injected knee compared to control knee (B-Il10−/−± α-GalCer n= 5 per group, B-WT± α-GalCer n= 6 per
group, one of two experiments is shown). b Analyzed on day 7 post disease onset, c, d, h analyzed on day 3 post disease onset, and e–i analyzed at 16 h
post disease onset. Data are mean± s.e.m. *p< 0.05, **p< 0.01, ***p< 0.001, and ****p< 0.0001 (a, i two-way ANOVA, b–g one-way ANOVA)
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deﬁcient mice (Fig. 6a, b). The disease progression in Cd1d−/− and
WT mice is shown in Supplementary Fig 11a.
To conﬁrm the involvement of CD1d in T2-MZP Breg-
suppressive function and in the differentiation of disease-
ameliorating iNKT cells, we isolated T2-MZP Bregs from the
spleens of WT, Jα18−/−, and Cd1d−/− mice in remission from
arthritis and transferred them into WT mice. T2-MZP Bregs from
WT and Jα18−/− mice (T2-MZP Bregs express CD1d in both
strains) suppressed arthritis and signiﬁcantly inhibited the
frequency of IFN-γ+CD4+ T cells in WT recipient mice (p<
0.01 by one-way ANOVA) (Fig. 6c, d). In contrast, T2-MZP
Bregs from Cd1d−/−mice failed to inhibit arthritis or to limit Th1/
Th17 responses in the recipient WT mice (Fig. 6e, f). Transfer of
WT and Jα18−/−T2-MZP, but not Cd1d−/− T2-MZP B cells,
caused an increase in iNKT cells producing IFN-γ (Fig. 6g). Of
note, we could not detect differences in IL-10 production by T2-
MZP B cells isolated from Cd1d−/− and WT mice (Supplementary
Fig. 11b). Our data demonstrate that suppression of arthritis by
T2-MZP Bregs requires both iNKT cells and CD1d.
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Redundant role of MZ B cells in α-GalCer suppression. MZ B
cells also express high levels of CD1d (Supplementary Fig. 9a, c)
and at least in vitro have been shown to exert suppression42. We
have previously reported that adoptively transferred MZ B cells
are unable to suppress arthritis in the recipient mice39, likely due
to their inability to repopulate the spleen. Next, we depleted MZ B
cells in WT mice, by administering anti-CD11a and anti-CD49d
antibodies43,44 prior to the induction of arthritis and treatment
with α-GalCer. Isotype-treated mice were used as controls. No
changes in the number of T2-MZP B cells were observed in MZ B
cell-depleted compared to control mice (Supplementary Fig. 12).
α-GalCer signiﬁcantly reduced the disease in both MZ B cell-
depleted and control mice (p< 0.05 by two-way ANOVA)
(Fig. 7a). The reduction in disease severity was accompanied by
iNKT cell expansion and increased expression of Ki-67 (Fig. 7b,
c). The induction of PLZF and IFN-γ expression in iNKT cells
from both MZ B cell-depleted and control mice was also com-
parable (Fig. 7d, e).
iNKT cells are dispensable for Breg development. Recently, it
has been shown that iNKT cells can induce the expansion of IL-
10-producing Bregs in a cognate manner45. We therefore
explored the existence of a feedback loop, whereby iNKT cells
support the differentiation of IL-10-producing Bregs. We did not
observe an enhancement of B cell IL-10 expression following
administration of α-GalCer to IL-10-eGFP reporter mice
(Fig. 8a). We induced arthritis in iNKT-cell-deﬁcient Jα18−/− and
Cd1d−/− mice to explore whether iNKT cells induced Bregs. As
shown before, B cell development was comparable in iNKT-cell-
deﬁcient and WT mice (Supplementary Fig. 13)32. We could not
ﬁnd any differences in the frequency of IL-10+ B cells and the
amount of IL-10 produced by B cells in response to different
stimuli in Jα18−/−, Cd1d−/−, and WT mice (Fig. 8b, c). These
results demonstrate that in this model iNKT cells are not required
for the differentiation of Bregs.
Discussion
Expression of CD1d is a hallmark of several described Breg phe-
notypes, including IL-10-producing B cells (B10), T2-MZP, and
MZ B cells2. Here, we show that the CD1d-dependent Breg
interaction with iNKT cells is critical for the differentiation of
iNKT cells with suppressive capacity.
B cells have diverse immunological functions, including pre-
sentation of peptide and lipid antigens. While the upregulation of
MHC class II molecules upon B cell activation promotes the
activation of CD4+ helper T cells, CD1d-dependent presentation
of α-GalCer by B cells to iNKT cells generates an activation signal
that drives antibody production18,19,46–48. Emerging evidence
shows that optimal CD1d expression on B cells is essential for the
generation of iNKT cell responses. For example, the loss of CD1d
expression on B cells, following Epstein–Barr virus infection,
results in severe attenuation of iNKT cell functions49. Data
from our laboratory and conﬁrmed by other groups1,50 suggested
that aberrant CD1d expression by B cells is associated with iNKT
cell functional defect observed in SLE patients. These ﬁndings
suggest that CD1d-mediated B-iNKT cell cross talk may be
important in iNKT cell homeostasis and for regulation of
suppression.
Using a combination of chimeric mice and adoptive transfer
strategies, we have demonstrated that CD1d+ Bregs inhibit
inﬂammation by directly interacting with iNKT cells, thus
underscoring a new mechanism for Breg suppression. It is
becoming increasingly clear that Bregs can suppress in an IL-10-
independent manner, including via IL-35, TGF-β, adenosine, or
PD-L14,5,51. In contrast to the induction of CD4+ Tregs by
Bregs52, which is impaired in the absence of IL-10+ B cells, here,
we show that the differentiation of iNKT cells that limit inﬂam-
mation in arthritis is CD1d-dependent but IL-10-independent.
Indeed, arthritis in B-Il10−/− or in global Il10ra−/− mice was
ameliorated by α-GalCer.
Several mechanisms for iNKT-cell-mediated regulation of
pathogenic T helper cell responses that drive autoimmunity have
been suggested11–13. For example, expression of IL-4, IL-10, and
IFN-γ has been shown to mediate iNKT-cell-dependent inhibi-
tion of autoimmunity13. We found that iNKT cell IFN-γ upre-
gulation was impaired in response to α-GalCer treatment in B
cell-deﬁcient or B-Cd1d−/− mice compared to control mice. The
protective role of iNKT cell IFN-γ in arthritis was supported by
the experiments where the neutralization of IFN-γ reversed the
protective effect of α-GalCer and restored the subsequent
proinﬂammatory cytokine production24. Grajewski et al. origin-
ally showed that iNKT cells producing IFN-γ ameliorate uveitis
by inhibiting the adaptive Th1 and Th17 responses, suggesting
that innate, iNKT-cell-produced IFN-γ is critical to initiate reg-
ulatory circuits that inhibit the differentiation of pathogenic T
helper cells in uveitis. In EAE and type 1 diabetes, iNKT cells
producing IFN-γ protect mice from developing the disease by
dampening CD4+ T cell activation, including their production of
IFN-γ and IL-1725,27,53. Of interest, at least in vitro iNKT cells
isolated from SLE patients produce less IFN-γ compared to
healthy individuals1. Although mice lacking B cells present a
signiﬁcant reduction in the frequency of IFN-γ+ iNKT cells
compared to control group, in response to α-GalCer, few IFN-γ+
iNKT cells are induced. This raises the question of why the
remaining iNKT cells fail to limit the severity of arthritis. It is
tempting to speculate, also based on the results in Fig. 5e, which
show that the maximum suppression of adaptive T cell responses
occurs in the presence of high levels of IFN-γ, that there may be a
dose effect of iNKT cells producing IFN-γ on the severity of
arthritis. Therefore, we propose that early (innate) production of
IFN-γ by iNKT cells is protective, but late (adaptive) production
Fig. 4 B cell inability to present α-GalCer affects iNKT cell expression of genes involved in cytokine responses and metabolism. a Scatter plot showing fold-
change relationships between common expressed genes (n= 5797) in iNKT cells from B-Cd1d−/− and B-WT mice that received α-GalCer or vehicle alone
following induction of arthritis (data sets from RNA-seq). Color gradient indicates the degree of difference in fold-change values between iNKT cells in B-
Cd1d−/− and B-WT mice following α-GalCer treatment. b Pathway enrichment analysis of pathways (right) showing enrichment among genes expressed
differentially in iNKT cells from B-Cd1d−/− and B-WT mice following α-GalCer treatment. It is presented as net pathway perturbation in iNKT cells from B-
Cd1d−/− mice compared to B-WT mice. Negative values mean inhibited in iNKT cells from B-Cd1d−/−, positive values mean activated in iNKT cells from B-
Cd1d. c Heat maps showing the expression of genes involved in glycolysis (top) and fatty acid oxidation (bottom) by iNKT cells from B-Cd1d−/− and B-WT
mice that received α-GalCer or vehicle alone. d Heat map showing the expression of cytokine genes by iNKT cells from B-Cd1d−/− and B-WT mice that
received α-GalCer or vehicle alone. e, f Volcano plots showing fold changes of differentially expressed genes associated with e NKT1 and NKT2
phenotypes, and f PLZF transcriptional regulation, between iNKT cells from B-Cd1d−/− and B-WT mice following α-GalCer treatment, plotted against p
values
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of IFN-γ (together with IL-17) by CD4+ T cells is associated with
increased inﬂammation and pathology. However, we cannot
exclude that in addition to IFN-γ, CD1d+ B cell-driven iNKT cells
suppress via other mechanisms yet to be unraveled.
In agreement with our data, several reports using different
experimental models of RA, including collagen-induced arthritis
(CIA) and glucose-6-phosphate isomerase (GPI)-induced arthri-
tis, have shown that α-GalCer ameliorates arthritis via inhibition
of proinﬂammatory cytokine production by CD4+ T cells54,55.
Coppieters et al. also showed that high levels of IFN-γ accumulate
in the serum of α-GalCer-treated mice and that neutralization of
IFN-γ at the time of α-GalCer administration during disease
onset reduced the efﬁcacy of the treatment, which again supports
our data showing that α-GalCer protection is mediated by IFN-γ+
iNKT cells54. In contrast to our results, it has been reported that
the protective role of α-GalCer in CIA was also mediated by an
upregulation of IL-10 by T cells, and that administration of an
anti-IL-10R antibody abrogated the protective effect56. In our
model, suppression of arthritis following α-GalCer was IL-10
independent as there was equivalent suppression of the disease in
α-GalCer-treated Il10ra−/− and WT mice. The same authors
reported different effects of α-GalCer treatment on cytokine
production between DBA/1 and C57BL/6 mice with CIA; higher
levels of serum IFN-γ were observed in C57BL/6 compared to
DBA/1 mice. This suggests that α-GalCer may mediate suppres-
sion differentially according to the disease model (CIA vs. AIA)
and to the genetic background of the mice (C57BL/6 vs.
DBA/1)56.
The induction of different populations of regulatory
iNKT cells, such as lymph node FoxP3+ iNKT cells28, adipose
tissue-enriched FoxP3−IL-10+ iNKT cells57, or adipose tissue-
resident FoxP3−PLZF−E4BP4+ iNKT cells29, has also been asso-
ciated with iNKT cell anti-inﬂammatory effects. Our data suggest
that Breg-induced iNKT cells are FoxP3−PLZF+E4BP4−. The
different phenotype may reﬂect the tissue from which they were
isolated, the particular inﬂammation model, or the stimuli
received from Bregs.
The comparative analysis of gene expression in iNKT cells
from B-Cd1d−/− and B-WT mice showed changes in several
regulatory pathways. In particular, in the absence of CD1d-
presenting B cells, we observed a downregulation of many genes
that are enriched in NKT1 cells and the upregulation of those
associated with NKT2 phenotype36. The expression of PLZF has
been linked with the acquisition and regulation of multiple facets
of iNKT cell phenotype, development, homeostasis, and
function22,23. Here, we consistently found PLZF expressed at
lower levels when B cells were unable to present α-GalCer.
Considering the central role of PLZF in establishing iNKT cell
function during differentiation and its maintenance in the per-
iphery, it is tempting to speculate that T2-MZP Bregs via CD1d,
and possibly other factors, may play a role in PLZF expression or
in the stabilization of PLZF locus. More detailed experiments
including the analysis of proximal conserved noncoding
sequences in the PLZF locus should be performed in the future to
assess this question in more detail. Taken together with the results
showing alteration in genes involved in immunometabolism in
iNKT cells from B-Cd1d−/− compared to B-WT mice, our data
suggest that Bregs expressing CD1d coordinate the induction of
iNKT cell effector program.
Recently, work carried out by Vomhof-DeKrey et al. showed
that 4-hydroxy-3-nitrophenyl-α-GalCer administration does not
induce humoral memory, but instead drives the expansion of IL-
10+ Bregs45. This suggests that iNKT cells provide pivotal signals
for Breg differentiation in vivo. In contrast to these data, we show
that Breg development is unaltered in mice lacking iNKT cells
and we could not observe an induction of IL-10+ B cells upon α-
GalCer treatment. iNKT cells isolated from α-GalCer-treated
AIA-immunized WT mice transferred disease suppression to
μMT mice (Supplementary Fig. 14) and Bregs failed to suppress
the disease in iNKT-cell-deﬁcient mice. Therefore, at least in our
experimental system, there is a “long-lasting” effect of B cell-
primed iNKT cells that persists following the transfer of
iNKT cells to a B cell-deﬁcient host.
Given that α-GalCer presentation by B cells to iNKT cells is
known to result in the differentiation of antibody-producing B
cells, we also investigated whether plasma cells were induced in
our model and whether they could regulate via the production of
IL-35. Following α-GalCer administration, we did not observe
induction of CD138+ plasmablasts (Supplementary Fig. 15a), or
any changes in Ebi3 or p35 mRNA levels by qPCR in B cells
(Supplementary Fig. 15b, c).
The lack of involvement of IL-35-producing plasmablasts in
this model was not entirely surprising as we have previously
published that mice lacking the p35 subunit of IL-35 develop
milder AIA compared to WT mice58. The decrease in disease
severity was mirrored by an increase in T2-MZP Bregs and a
decrease in MZ B cells. We have also shown that T2-MZP or B
cells stimulated with anti-CD40, isolated from p35-deﬁcient mice
protect against AIA upon adoptive transfer to recipient mice.
Therefore, in this system, IL-35 does not seem to play a regulatory
function.
CD1d is associated with a Breg phenotype. In a spontaneous
model of colitis, B cells isolated from CD1d-deﬁcient mice failed
to suppress the disease when transferred to TCRα−/− mice,
Fig. 5 α-GalCer-mediated amelioration of arthritis is partially dependent on IFN-γ production by iNKT cells. a Top, mean clinical score of anti-IFN-γ-treated
and isotype-control-treated WT mice that received α-GalCer or vehicle alone following induction of arthritis. The Y axis shows the percentage of swelling in
antigen-injected knee compared to control knee. Bottom, bar chart showing the suppression of knee swelling in anti-IFN-γ-treated and isotype-control-
treated WT mice that received α-GalCer, compared to anti-IFN-γ-treated and isotype-control-treated WT mice that received vehicle alone (anti-IFN-γ-
treated WT± α-GalCer n= 5 per group, isotype-control-treated WT± α-GalCer n= 4 per group, one of two experiments is shown). b Representative ﬂow
cytometry plots (top) and bar charts (bottom) showing the frequency and number of splenic IFN-γ+ and IL-17+ CD4+ T cells in anti-IFN-γ-treated and
isotype-control-treated WT mice that received α-GalCer or vehicle alone (n= 3 per group, one of two experiments is shown). c Representative ﬂow
cytometry plots (top) and bar charts (bottom) showing the frequency of T-bet+, ROR-γt+, and GATA3+ CD4+ T cells in μMT and WT splenocyte cultures
with α-GalCer and isotype control or α-GalCer and anti-IFN-γ-blocking antibodies (μMT n= 3, WT n= 6, one of two experiments is shown). d
Representative ﬂow cytometry plots (top) and bar chart (bottom) showing the frequency of IFN-γ+CD4+ T cells following coculture with in vivo α-GalCer-
stimulated iNKT cells (or alone), isolated from the spleens of arthritic μMT and WT mice in the presence of IFN-γ-neutralizing or isotype-control antibodies
(n= 4 per condition, one of two experiments is shown). e Bar charts showing the frequency of T-bet+ (left) and ROR-γt+ (right) CD4+ T cells, isolated from
the spleens of arthritic WT mice, following stimulation with increasing concentrations of IFN-γ (n= 3 per condition, one of two experiments is shown). b
Analyzed on day 3 post disease onset. Data are mean± s.e.m. ns not signiﬁcant, *p< 0.05, **p< 0.01, ***p< 0.001, and ****p< 0.0001 (a two-way
ANOVA, b–e one-way ANOVA)
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conﬁrming the importance of CD1d in the regulatory function of
B cells. In colitis, Breg-mediated suppression required IL-10 and
not iNKT cells, as B cells could still suppress in the absence of
iNKT cells. Similarly, Bregs, induced in response to S. mansoni,
suppress allergic airway inﬂammation in mice in a CD1d-
dependent, but iNKT-cell-independent manner7. Differences
between our results and those previously published could
be attributed to the fact that while AIA is a Th1-driven model,
both colitis in TCRα−/− mice and S. mansoni-induced
allergic airway inﬂammation are Th2 driven. It is conceivable that
B cells expressing CD1d may inhibit Th1 and Th2 cell responses
differently (e.g., via iNKT cells in Th1- and via IL-10 in Th2-
driven models). In addition, activation of epithelial cells using
an anti-CD1d antibody has been shown to induce the upregula-
tion of IL-10 in the epithelial cells59. Thus, direct activation of
CD1d-expressing cells, in the absence of iTCR ligation, could
provide an additional explanation for the CD1d-dependent but
iNKT-cell-independent and IL-10-mediated effects reported by
others59.
Previous work has shown that in an in vivo killing assay,
α-GalCer-loaded, CD1d-expressing cells, in particular MZ B cells
and to a certain extent CD11c+ and CD11b+ cells are killed68.
In arthritis, we found that splenic B cell subset frequencies
were not reduced and the numbers of each subset were increased
in α-GalCer-treated B-WT mice. In α-GalCer-treated B-Cd1d−/−
mice, MZ B cell frequency was reduced (Supplementary Fig. 16).
MZ B cells express higher levels of CD1d than T2-MZP B
cells; however, our results show that MZ B cell depletion does
not impair the induction of suppressive iNKT cells following
α-GalCer treatment. We have also shown that there were 50%
less IFN-γ+ iNKT cells in the liver compared to the spleen after
α-GalCer treatment of arthritic mice. T2-MZP B cells do not
reside in the liver (Supplementary Fig. 17) and in this organ, the
majority of B cells are follicular which express low levels of CD1d,
providing indirect evidence that T2-MZP Bregs are important
for the differentiation of suppressive IFN-γ+ iNKT cells.
One possible explanation of how MZ B cells contribute differ-
entially to iNKT-cell-driven disease outcome is the location.
To exclude a role for MZ B cells, the effect of α-GalCer in
the absence of T2-MZP B cells should be assessed. However, this
is technically impossible, thus leaving open the possibility that
MZ B cells may be important for the α-GalCer-mediated
suppression.
In conclusion, we have described a T2-MZP Breg regulatory
mechanism that acts as a rheostat in the differentiation of
iNKT cells with suppressive capacity. In an era where B cells
constitute a primary therapeutic target in several autoimmune
diseases and in cancer, these data add a further degree of com-
plexity that needs to be considered when designing new therapies
aimed to eliminate the entirety of B cells.
Methods
Mice. C57BL/6 mice were from Harlan Laboratories (now Envigo Laboratories).
μMT60 (stock no: 002288), Cd1d−/−41 (stock no: 008881), and II10−/−61 (stock no:
002251) mice were from The Jackson Laboratory. CD11c-DTR mice62 were pro-
vided by C. Bennett, University College London, UK and were originally from The
Jackson Laboratory (stock no: 004509). Jα18−/− mice40 were provided by A. Kar-
adimitris, Imperial College London, UK. Il10ra−/− mice63 were provided by W.
Muller, University of Manchester, UK. IL-10 transcriptional reporter (Vert-X)
mice64 were provided by C. Karp, Bill & Melinda Gates Foundation. All mice were
on C57BL/6 background. Mice were age- and sex-matched (males), and used at
6–12 weeks of age. Mice were bred and maintained under speciﬁc pathogen-free
(SPF) conditions at the animal facility at University College London, UK. All
experiments were approved by the Animal Welfare and Ethical Review Body of
University College London and authorized by the United Kingdom Home Ofﬁce.
Induction of antigen-induced arthritis. AIA was induced52. Male mice were
immunized subcutaneously at the tail base with 200 μg of methylated bovine serum
albumin (mBSA, Sigma-Aldrich) in 200 μl of complete Freund’s adjuvant (CFA)
and phosphate-buffered saline (PBS, Sigma-Aldrich). A concentration of 3 mg/ml
CFA was prepared by mixing of Mycobacterium tuberculosis (Difco) in incomplete
Freund’s adjuvant (IFA, Sigma-Aldrich). After 7 days, mice received an intra-
articular injection of 200 μg of mBSA in 10 μl of PBS in the right knee or PBS alone
as a control in the left knee. Joint size was measured using POCO 2-T calipers
(Kroeplin Längenmesstechnik), and swelling was calculated as percentage increase
in size between antigen- and control-injected knee.
Administration of α-galactosylceramide. When treated with α-
galactosylceramide (α-GalCer, Enzo Life Sciences), mice received an intraperitoneal
injection of 2 μg of α-GalCer in 200 μl of 0.5% DMSO (Sigma-Aldrich) in PBS at
the time of the intra-articular injection, unless otherwise indicated. As a control, a
separate group of mice was treated with 200 μl of 0.5% DMSO in PBS.
B cell depletion. For B cell depletion, mice were treated intraperitoneally with 200
μg of anti-CD20 antibodies (5D2, Genentech) in 200 μl of PBS, or isotype-control
antibodies (IgG2a, 400502, Biolegend) in PBS, on days −21, −14, and −7 prior to
intra-articular injection to induce AIA.
CD11c+ cell depletion. CD11c-DTR mice were treated intraperitoneally with 100
ng of diphtheria toxin from Corynebacterium diphtheriae (Sigma-Aldrich) in 200 μl
of PBS, or PBS alone as control31 at the time of intra-articular injection to induce
AIA, and 8 h prior to α-GalCer or vehicle administration.
Fig. 6 T2-MZP Bregs mediate suppression via iNKT cells and require CD1d. a Top, schematic showing the experimental design. Bottom, bar chart showing
suppression of knee swelling in Cd1d−/− and WT mice that received T2-MZP B cells, isolated from the spleens of WT mice on day 7 post disease onset,
compared to Cd1d−/− and WT mice that received no transfer (Cd1d−/− n= 11, WT n= 16, one of two experiments is shown). b Representative ﬂow
cytometry plots (left) and bar charts (right) showing the frequency and number of splenic IFN-γ+ and IL-17+ CD4+ T cells in Cd1d−/− and WT mice that
received T2-MZP B cells, isolated from the spleens of WT mice on day 7 post disease onset, or Cd1d−/− and WT mice that received no transfer (n= 3 per
group, one of two experiments is shown). c Top, schematic showing the experimental design. Bottom, mean clinical score of WT mice that received T2-
MZP B cells, isolated from the spleens of Jα18−/− or WT mice on day 7 post disease onset, or WT mice that received no transfer following induction of
arthritis. The Y axis shows the percentage of swelling in antigen-injected knee compared to control knee (Jα18−/− T2-MZP transfer n= 4, WT T2-MZP
transfer n= 3, no transfer n= 4, one of two experiments is shown). d Representative ﬂow cytometry plots (top) and bar charts (bottom) showing the
frequency and number of splenic IFN-γ+ and IL-17+CD4+ T cells in WT mice that received T2-MZP B cells, isolated from the spleens of Jα18−/− or WT mice
on day 7 post disease onset, or WT mice that received no transfer (n= 4 per group, one of two experiments is shown). e Top, schematic showing the
experimental design. Bottom, mean clinical score of WT mice that received T2-MZP B cells, isolated from the spleens of Cd1d−/− or WT mice on day 7 post
disease onset, or WT mice that received no transfer following induction of arthritis. The Y axis shows the percentage of swelling in antigen-injected knee
compared to control knee (n= 6 per group, one of two experiments is shown). f Representative ﬂow cytometry plots (top) and bar charts (bottom)
showing the frequency and number of splenic IFN-γ+ and IL-17+CD4+ T cells in WT mice that received T2-MZP B cells, isolated from the spleens of Cd1d−/−
or WT mice on day 7 post disease onset, or WT mice that received no transfer (n= 4 per group, one of two experiments is shown). g Representative ﬂow
cytometry plots and bar chart showing the frequency of IFN-γ+ splenic iNKT cells in WT mice that received T2-MZP B cells, isolated from the spleens of
Cd1d−/− or WT mice on day 7 post disease onset, or WT mice that received no transfer (n= 4 per group, one of two experiments is shown). b, d, f, g
Analyzed on day 3 post disease onset. Data are mean± s.e.m. ns not signiﬁcant, *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001, ••p< 0.01, and •••p<
0.001 (a, c, e two-way ANOVA; b, d, f one-way ANOVA)
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Marginal zone B cell depletion. For marginal zone B cell depletion, mice were
treated intraperitoneally with 100 μg of each anti-CD11a (M17/4, eBioscience) and
anti-CD49d (cR1-2, Biolegend), or isotype-control antibodies (IgG2a, 400502,
Biolegend), 16 h prior to intra-articular injection to induce AIA.
In vivo IFN-γ neutralization. For IFN-γ neutralization, mice were treated intra-
peritoneally with 200 μg of anti-IFN-γ antibodies (XMG1.2, BioXCell) in 200 μl of
PBS, or isotype-control antibodies (IgG1, 400402, Biolegend) in PBS 2 days prior to
intra-articular injection, and at day 0 of and 2 days post intra-articular injection
with mBSA.
Cell preparation. Spleens and livers were collected in complete RPMI-1640 with L-
glutamine and NaHCO3 (cRPMI, Sigma-Aldrich) with 1:10 FBS (Biosera), 1:100
penicillin (10,000 units/ml)/streptomycin (10 mg/ml) (Sigma-Aldrich), and 1:1000
50 mM 2-mercaptoethanol (Gibco, Invitrogen). Single-cell suspensions were
obtained by dissociating the tissue through 70-μM cell strainers (BD Biosciences),
and erythrocytes in spleens were lysed using red blood cell (RBC) lysis buffer
(Sigma-Aldrich). For the isolation of liver mononuclear cells, Percoll (Amersham
Biosciences) 30%/70% gradient was used with subsequent RBC lysis.
Generation of mixed bone marrow chimeric mice. Mixed BM chimeric mice
were generated. Brieﬂy, recipient WT mice received 8 Gy of γ-irradiation via a
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cesium (137Cs) source. Recipient mice were allowed to equilibrate for 5 h before
administering 107 donor BM cells. To restrict genetic deﬁciency of CD1d or IL-10
to B cells, lethally irradiated (8 Gy) WT mice were reconstituted with a mixture
consisting of 80% BM from μMT mice and 20% BM from Cd1d−/− or Il10−/− mice.
Control mice received 80% BM from μMT mice and 20% BM from WT mice. The
efﬁciency of irradiation of WT mice was conﬁrmed by the absence of B cells in
mice reconstituted with 100% μMT BM. Chimeric mice were left to reconstitute for
at least 8 weeks prior to use in AIA experiments.
Adoptive transfer. T2-MZP B cells were isolated from the spleens of Jα18−/−,
Cd1d−/−, or WT mice on day 7 post disease onset by ﬂuorescence-activated cell
sorting (FACS). iNKT cells were isolated from the spleens of WT mice on day 3
following α-GalCer treatment by FACS. A total of 2 × 106 T2-MZP B cells or
iNKT cells were then transferred intravenously to Cd1d−/− and WT, or μMT and
WT mice, respectively, immediately following induction of arthritis. The control
group received a Hanks’ Balanced Salt Solution (Sigma-Aldrich) injection.
Flow cytometry and ﬂuorescence-activated cell sorting. Single-cell suspensions
were incubated with FcR-blocking reagent for the mouse (Miltenyi Biotec) prior to
staining with speciﬁc antibodies (Supplementary Table 1) and CD1d tetramers.
CD1d tetramers were conjugated to PE, AF488, APC, and AF647 and loaded with
PBS57 or left unloaded, and were obtained from the National Institutes of Health
Tetramer Core Facility. Tetramer staining was carried out prior to surface antibody
staining. All staining was performed at 4 °C for 30 min. For transcription factor and
Ki-67 staining, cells were ﬁxed and permeabilized using Foxp3/Transcription
Factor Staining Buffer Set (00-5523-00, eBioscience) according to the manu-
facturer’s instructions. For the detection of IFN-γ and IL-17, cells were stimulated
for 5 h in cRPMI with 50 ng/ml phorbol 12-myristate 13-acetate (PMA) and 250
ng/ml ionomycin (both from Sigma-Aldrich). For the detection of IL-10, cells were
stimulated for 5 h in cRPMI with 100 ng/ml PMA and 1000 ng/ml ionomycin.
Protein transport inhibitor (either containing brefeldin A or monensin, both from
BD Biosciences) was added during stimulations according to the manufacturer’s
instructions. Cells were then stained for surface markers, ﬁxed, and permeabilized
using Intracellular Fixation & Permeabilization Buffer Set (88-8824-00,
eBioscience) according to the manufacturer’s instructions. Dead cells were exclu-
ded with LIVE/DEAD Fixable Dead Cell Stains or DAPI (both from Invitrogen).
Flow cytometry was performed on LSRFortessa, LSRFortessa X-20, LSRII, and cell
sorting on FACSAria cell sorter (all from BD Biosciences). Data were analyzed
using FlowJo (Treestar).
Immunoﬂuorescence. Spleens were dissected, embedded in OCT compound
(Tissue-Tek), and snap-frozen for cryosectioning (6 µm). Slides were then incu-
bated in 100% ethanol to ﬁx for 5–10 min (4 °C), followed by rehydration in PBS
for 5 min (4 °C). The sections were blocked with 10% normal goat serum for 20
min at room temperature (RT), and then rinsed with PBS. The tissues were
incubated with primary antibodies for 1 h at RT and then washed 3× in PBS (2 min
for each wash). When secondary antibodies were used, the tissue was further
incubated with the secondary antibody for 1 h at RT, again followed by three
washes in PBS (2 min for each wash). The slides were ﬁnally mounted in Prolong
Antifade Mountant with DAPI (Thermo Fisher), imaged on a Leica SPE confocal
microscope using LAS X software, and analyzed using Fiji (ImageJ).
In vitro B cell culture. Splenic B cells were negatively puriﬁed (>95%) by magnetic
separation using CD43 (Ly-48) microbeads (Miltenyi Biotec) and cultured for 72 h
with 10 μg/ml mBSA, 10 μg/ml anti-CD40 (FGK4.5, BioXCell), or mBSA+anti-
CD40. Supernatants from cell cultures were harvested and IL-10 was measured
using mouse IL-10 DuoSet ELISA (DY417, R&D Systems) according to the
manufacturer’s instructions.
In vitro iNKT cell suppression assay. Splenic iNKT cells from arthritic μMT and
WT mice were sorted by FACS 16 h following α-GalCer treatment. iNKT cells were
then cocultured at a ratio of 1:1 with CD4+CD25− T cells, isolated from the spleens
of WT mice 16 h following intra-articular injection to induce arthritis by magnetic
separation (Miltenyi Biotec), for 72 h in the presence of 0.5 μg/ml plate-bound anti-
CD3 (145-2C11, BD Biosciences). PMA, ionomycin, and protein transport
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Fig. 8 Regulatory B cell development and in vitro suppressive capacity are not impaired in iNKT-cell-deﬁcient mice. a Representative ﬂow cytometry plots
and bar charts showing the frequency and number of splenic IL-10-eGFP+CD19+ B cells from IL-10-eGFP mice that received α-GalCer or vehicle alone
following induction of arthritis (α-GalCer-treated group n= 4, vehicle-treated group n= 3, one of two experiments is shown). b Representative ﬂow
cytometry plots and bar charts showing the frequency and number of splenic IL-10+CD19+ B cells in Jα18−/−, Cd1d−/−, and WT mice following arthritis
(Jα18−/− n= 5, Cd1d−/−n= 8, and WT n= 9, one of two experiments is shown). c Bar chart showing IL-10 production by B cells isolated from the spleens of
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inhibitor were added for the last 6 h of culture. Following stimulation, cells were
analyzed for the expression of IFN-γ by ﬂow cytometry.
In vitro B cell and dendritic cell depletion. Splenocytes were negatively depleted
of B cells (CD19) or dendritic cells (CD11c) by FACS and stimulated with IL-2 (80
U/ml, Miltenyi Biotec) in the presence of 100 ng/ml α-GalCer for 48 h.
RNA sequencing. Splenic iNKT cells from B-Cd1d−/− and B-WT mice that
received α-GalCer or vehicle as control were sorted by FACS. Sorted cells were
>95% pure. Total RNA was isolated using PicoPure RNA Isolation Kit (KIT0204,
Applied Biosystems) according to the manufacturer’s instructions. cDNA was
synthesized and ampliﬁed using SMARTer v4 Ultra Low Input Kit (634888,
Clontech). A total of 200 pg of ampliﬁed cDNA was then converted to a sequencing
library using the Nextera XT Kit (FC-131-1024, Illumina, 12 cycles of PCR).
Samples were individually indexed during library preparation, which allowed
pooling and sequencing on the Illumina NextSeq 500 platform (43-bp paired end).
An average of 18M read pairs was obtained for each sample. Reads were adapter
trimmed (FASTX-Toolkit) and aligned to theMus musculus genome (mm10) using
Tophat v2.0.7.
Bioinformatics analysis of RNA-seq data. Differential expression analysis was
performed using the edgeR algorithm65 under default settings. Genes with false-
discovery rate (FDR) values <0.05 were considered to be differentially expressed.
Signiﬁcantly overrepresented pathways were identiﬁed using signaling pathway
impact analysis (SPIA)66. Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways database67 was used as a reference, while full mouse genome was used as
a background for enrichment.
Statistical analysis. All data are expressed as mean ± s.e.m. Replicates were bio-
logical replicates. Clinical scoring was performed blinded. Mice were assigned to
treatment groups at random for all mouse studies and, where possible, mixed
among cages. Careful consideration has been given to calculate the number of mice
needed to give statistically signiﬁcant results, while using the minimum number of
mice possible. Numbers of mice for each experiment were decided after con-
sultation with a statistician at UCL. For in vivo studies, power calculations were
based on data showing mean maximum wild-type arthritic knee swelling of 2 mm
with an s.d. of 0.39 mm, and an expected test group arthritic knee swelling of ±0.6
mm compared to control group depending on the experiment. Group sizes of 5 or
above were sufﬁcient to reach a statistical power of at least 80%. Further, experi-
ments were performed independently in triplicate to control for experimental
variation. Groups were compared with two-tailed Student’s t test, or one- or two-
way analysis of variance (ANOVA) followed by Bonferroni posttest with Prism
(GraphPad). Data followed Gaussian distribution with similar variance between
groups that were compared.
Data availability. The RNA-seq data have been deposited in ArrayExpress under
E-MTAB-6381. The authors declare that the data supporting the ﬁndings of this
study are available within the article and its supplementary information ﬁles, or are
available upon reasonable requests to the authors.
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